Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.2 to v2.16.3.
    Difference
    0.0%
    Check dated 2025-06-13T15:59:03.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-06T09:34:26.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    0.8%
    Check dated 2025-05-30T04:30:35.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The web page has been updated to version 2.16.0, replacing the previous version 2.15.2.
    Difference
    0.1%
    Check dated 2025-05-23T01:23:49.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    The page has removed a citation for a clinical trial regarding Cabozantinib versus Sunitinib for metastatic renal cell carcinoma, which included important erratum details.
    Difference
    0.4%
    Check dated 2025-05-08T13:09:13.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.0%
    Check dated 2025-05-01T05:50:26.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.